Keros Therapeutics (KROS) Enterprise Value (2019 - 2025)
Keros Therapeutics posted quarterly Enterprise Value of -$287.4 million for Q4 2025, up 48.67% year-on-year from -$193.3 million in Q4 2024, and up 58.56% on a QoQ basis from -$693.5 million in Q3 2025.
Keros Therapeutics (KROS) has 7 years of Enterprise Value data on file, last reported at -$287.4 million in Q4 2025.
- For the quarter ending Q4 2025, Enterprise Value rose 48.67% year-over-year to -$287.4 million; the trailing twelve-month figure through Dec 2025 stood at -$287.4 million (up 48.67% YoY), and the FY2025 full-year result was -$287.4 million, up 48.67% from the prior year.
- Enterprise Value for Q4 2025 stood at -$287.4 million, up from -$693.5 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$215.6 million in Q2 2022 and bottomed at -$720.5 million in Q1 2025.
- The 5-year median for Enterprise Value is -$305.0 million (2023), against an average of -$376.5 million.
- The widest annual swing landed in 2021, when Enterprise Value slumped 368.11%; it then soared 48.67% in 2025.
- A 5-year view of Enterprise Value shows it stood at -$230.0 million in 2021, then fell by 21.3% to -$279.0 million in 2022, then decreased by 18.67% to -$331.1 million in 2023, then plunged by 69.09% to -$559.9 million in 2024, then jumped by 48.67% to -$287.4 million in 2025.
- The last three Enterprise Value figures came in at -$287.4 million (Q4 2025), -$693.5 million (Q3 2025), and -$690.2 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.32 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -32.30 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -286.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -61.46 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.77 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -7.25 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -18.44 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -8.75 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -3.01 Bn |
| 10 | Keros Therapeutics | 403.85 Mn | 116.45 Mn | - | -287.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -287.40 Mn |
| Sep 30, 2025 | -693.47 Mn |
| Jun 30, 2025 | -690.22 Mn |
| Mar 31, 2025 | -720.54 Mn |
| Dec 31, 2024 | -559.93 Mn |
| Sep 30, 2024 | -530.68 Mn |
| Jun 30, 2024 | -405.86 Mn |
| Mar 31, 2024 | -442.44 Mn |
| Dec 31, 2023 | -331.15 Mn |
| Sep 30, 2023 | -287.89 Mn |
| Jun 30, 2023 | -322.03 Mn |
| Mar 31, 2023 | -351.43 Mn |
| Dec 31, 2022 | -279.05 Mn |
| Sep 30, 2022 | -239.43 Mn |
| Jun 30, 2022 | -215.62 Mn |
| Mar 31, 2022 | -228.59 Mn |
| Dec 31, 2021 | -230.04 Mn |
| Sep 30, 2021 | -221.35 Mn |
| Jun 30, 2021 | -237.11 Mn |
| Mar 31, 2021 | -255.20 Mn |
| Dec 31, 2020 | -265.88 Mn |
| Sep 30, 2020 | -133.81 Mn |
| Jun 30, 2020 | -144.69 Mn |
| Mar 31, 2020 | -54.52 Mn |
| Dec 31, 2019 | -7.02 Mn |
| Sep 30, 2019 | -12.53 Mn |
| Jun 30, 2019 | -15.55 Mn |
| Mar 31, 2019 | -20.75 Mn |